AI Thai Food App and CGM Monitoring Pilot Study for Type 2 Diabetes
Summary
NIH's ClinicalTrials.gov has registered NCT07533604, an 8-week randomized controlled pilot study evaluating an AI-powered Thai food analysis application (SnapD) combined with continuous glucose monitoring (CGM) for glycemic control in 45 patients with Type 2 Diabetes and overweight/obesity. The study has three arms: SnapD alone, SnapD with CGM, or standard diabetes self-management education. Participants will be monitored over 8 weeks with HbA1c as the primary endpoint.
What changed
This document registers a new clinical trial on ClinicalTrials.gov, not a regulatory rule or guidance. The study will evaluate an AI-powered smartphone application (SnapD using Gemini 2.5 Flash) designed to recognize Thai food and estimate nutritional values, combined with Linx CGM devices, for managing Type 2 Diabetes.
For healthcare providers and clinical investigators, this represents a potential research collaboration opportunity or referral pathway for eligible patients. The study's findings could inform future clinical applications of AI in dietary management for diabetes care.
What to do next
- Monitor ClinicalTrials.gov for study updates
- Review inclusion/exclusion criteria for potential patient enrollment
- Contact study investigators for participation details
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SnapDandCGMinType2Diabetes
N/A NCT07533604 Kind: NA Apr 16, 2026
Abstract
Study Title: The Effectiveness of an AI-powered Thai food analysis (SnapD) and Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes and Overweight or Obesity: A Randomized Controlled Pilot Study Rationale: Effective dietary management is the cornerstone of treating Type 2 Diabetes (T2DM) and obesity. However, traditional manual food logging is often inaccurate and burdensome. While digital tools and Continuous Glucose Monitoring (CGM) have shown promise internationally, there is a lack of validated AI-powered tools specifically designed for Thai cuisine. This study introduces SnapD, an AI-powered platform (utilizing Gemini 2.5 Flash) designed to recognize Thai food, estimate nutritional values, and integrate with CGM data to provide personalized feedback.
The primary goal of this pilot study is to evaluate the efficacy of the SnapD application, both as a standalone tool and in combination with CGM, compared to Standard of Care in improving glycemic control (HbA1c) over 8 weeks. Additionally, the study aims to assess the feasibility, participant adherence, and safety of these digital interventions to inform a future, fully powered randomized controlled trial.
Study Design: This is an 8-week, randomized, open-label, parallel-group, superiority pilot study with a 1:1:1 allocation ratio. A total of 45 participants will be enrolled and assigned to one of three arms:
- Intervention Arm 1: SnapD application + Real-time CGM + Diabetes Self-Managem...
Conditions: Type2 Diabetes Mellitus
Interventions: SnapD, Linx CGM, Diabetes Self-Management Education (DSMES)
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.